Use cost-effective, rapid, and large-scale cancer cell line screening to advance your lead compound to validated candidate. OmniScreen provides key information on the cytotoxicity and chemotherapeutic potential of your agent early in the drug development process.
|Registration Deadline||Study Initiation|
|April 28, 2023||May 11, 2023|
|July 30, 2023||August 10, 2023|
|November 5, 2023||November 15, 2023|
|February 6, 2024||February 17, 2024|
Take advantage of our quarterly revival of over 500 cancer cell lines, providing you significant cost savings.
Highlights of OmniScreen:
OmniScreen: Crown Bioscience’s Large-Scale Cell Line Screening Panel Platform
Our OmniScreen cancer cell line panels include:
OmniPanel™, a genomically diverse and growing collection of more than 500 cancer cell lines for drug response screening
XenoSelect™, a diverse oncogenic in vitro screening panel of more than 150 well validated cell lines with corresponding xenograft models ready for in vivo efficacy studies
RNAseq Panel, more than 170 in-house genomically characterized cell lines to correlate mutation status, copy number variation, and expression levels with drug response.
PrimePanel™, over 35 unique human disease-relevant cell lines derived from our patient-derived xenograft (PDX) models.